Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat

Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat

Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales

BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales

Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET

Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal

Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why

Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study

Corcept (CORT) Completes Enrollment in Phase II ALS Study

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft

Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug